KOD News and Press, Kodiak Sciences Inc From 12/04/19

Kodiak Sciences (NASDAQ: KOD ) has priced its public offering of 6M common shares at $46.00 per share, for expected gross proceeds of ~$276M. More news on: Kodiak Sciences Inc., Healthcare stocks news, Stocks on the move, Read more ...

PALO ALTO, Calif. , Dec. 3, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an underwritten public offering of 6,0...

PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has commenced an underwritten public offering of ...

Gainers:  Kodiak Sciences (NASDAQ: KOD )  +70% . More news on: Kodiak Sciences Inc., ASLAN Pharmaceuticals Limited, Cortexyme, Inc., Stocks on the move, Read more ...

Shares of Kodiak Sciences (NASDAQ: KOD) were skyrocketing 85.8% higher as of 10:41 a.m. EST on Monday after rising as much as 146.5% earlier in the day. This huge jump was spurred by Kodiak's announcement that it was selling a capped 4.5% royalty right on potential global net sales of experi...

Kodiak Sciences (NASDAQ: KOD )  +6.6%  in pre market as the Company agrees to sell a capped 4.5% royalty right on global net sales of KSI-301 to Baker Bros. Advisors, for $225M More news on: Kodiak Sciences Inc., Healthcare stocks news, Read more ...

PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Evercore ISI Heal...

PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million . KSI-301 is Kodiak's inve...

Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...

Buying stocks just because they're going up is a great way to lose a lot of money, but that doesn't mean you should avoid every company that's signaling signs of success. These three small-cap biotech stocks have been rocketing higher all year and for good reasons. They're all heading toward th...